|
gptkbp:instanceOf
|
gptkb:public_company
|
|
gptkbp:CEO
|
gptkb:Yvonne_Greenstreet
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:CUSIP
|
02043Q107
|
|
gptkbp:focusesOn
|
RNA interference therapeutics
|
|
gptkbp:foundedBy
|
gptkb:David_Bartel
gptkb:John_Maraganore
gptkb:Phillip_Zamore
gptkb:Thomas_Tuschl
Paul N. Monahan
|
|
gptkbp:foundedYear
|
2002
|
|
gptkbp:hasCompany
|
gptkb:Alnylam_Pharmaceuticals,_Inc.
|
|
gptkbp:hasPatent
|
RNAi therapeutics
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NASDAQ:ALNY
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:ISIN
|
US02043Q1076
|
|
gptkbp:market
|
gptkb:NASDAQ_Global_Select_Market
|
|
gptkbp:numberOfEmployees
|
~2000
|
|
gptkbp:product
|
gptkb:AMVUTTRA
gptkb:GIVLAARI
gptkb:ONPATTRO
gptkb:OXLUMO
|
|
gptkbp:sector
|
gptkb:insurance
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:ALNY
|
|
gptkbp:subsidiary
|
Alnylam Pharmaceuticals Securities Corporation
Alnylam U.S., Inc.
|
|
gptkbp:tickerType
|
gptkb:stock_market_index
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:ALNY
|
|
gptkbp:website
|
https://www.alnylam.com/
|
|
gptkbp:bfsParent
|
gptkb:ALNY
|
|
gptkbp:bfsLayer
|
8
|